Approval · Notice of Compliance 10148 · 2009
ELIGARD: Notice of Compliance 10148
Issued April 9, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10148
- Date
- April 9, 2009
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision to Indication and Clinical Use, Dosage and Administration, and Consumer Information sections of the Product Monograph: Eligard should be administered by a health care professional
- Therapeutic class
- Luteinizing hormone-releasing hormone analog
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ELIGARD | Not yet assigned | — |
Medicinal ingredients
- LEUPROLIDE ACETATE 10.2 MG per SYR
- LEUPROLIDE ACETATE 28.2 MG per SYR
- LEUPROLIDE ACETATE 35.8 MG per SYR
- LEUPROLIDE ACETATE 58.2 MG per SYR